Solventum : Quarterly Financial Update Q1 2026
SOLV
Published on 05/05/2026 at 04:44 pm EDT - Modified on 05/05/2026 at 04:45 pm EDT
Solventum at a glance
At Solventum, we enable better, smarter, safer healthcare to improve lives. Across our businesses - Medical Surgical (MedSurg), Dental Solutions and Health Information Systems (HIS) - we have strong positions in diverse and growing markets, trusted and recognized brands and global commercial scale and reach.
70+
year history of innovation
6,700+
patents issued
20,000+
employees
100,000+
customers and channel partners globally in 90+ countries
Business segments at a glance
Business segment
Total company sales1
Growth drivers
Q1 2026 highlights
MedSurg
Provides advanced wound care, infection prevention and surgical supplies that are intended to accelerate healing, prevent complications and lower the total cost of care globally.
61%
Negative pressure wound therapy
IV site management
Sterilization assurance
Specialized commercial organization delivering results
Strong brand equity
Momentum from recent product launches in infection prevention and surgical solutions
Dental Solutions
Offers the most comprehensive dental solutions for patients to enjoy healthy, beautiful smiles through game-changing innovation.
18%
Core restoratives
Strong existing brands
Recent product launches and sales channel specialization
Health Information Systems
Delivers innovative software solutions and services, designed to eliminate revenue cycle waste, create more time to care and support the shift to value-based care.
17%
Revenue cycle management
Growth in revenue cycle management
International expansion
Progress in autonomous coding with customers and partners
1 Calculated as % of Q1 2026 net sales.
Q1 financial
highlights*
Sales
$
2.0B
(3.0)% total sales growth
Diluted GAAP EPS
$
0.07
+2.1% organic sales growth
* See non-GAAP flnancial measures and
reconciliation schedules included in our earnings release dated May 5, 2026, which can be found on our investor relations website.
Operating cash flow
$
(189)M
Adjusted diluted EPS
$
1.48
2026 guidance
Growth and margin expansion in 2026
Organic sales growth
+2.0% to +3.0%
+3.0% to +4.0% excluding ~100 bps
of SKU exit impact
Adjusted diluted EPS
$6.40 to $6.60
estimated to be toward the top end of the range
Free cash flow
~$200M
Business segment
Reported sales growth
Organic sales growth
MedSurg
+6.6%
+1.2%
Dental Solutions
+7.9%
+3.4%
Health Information Systems
+4.1%
+4.7%
Segment highlights
Strong progress propelled by growth drivers
This communication and other materials Solventum has flled or will flle with the U.S. Securities & Exchange Commission ("SEC") (and oral communications that Solventum may make) contain or incorporate by reference statements that relate to future events and expectations and, as such, constitute forward-looking statements that involve risk and uncertainties. Forward-looking statements include those containing such words as "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "guidance," "intends," "may," "outlook," "plans," "projects," "seeks," "sees," "should," "targets," "will," "would" or other words of similar meaning. All statements that reflect Solventum's expectations, assumptions or projections about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, forecasts relating to discussions of future operations and flnancial performance (including volume growth, pricing, sales and earnings per share growth and cash flows) and statements regarding Solventum's strategy for growth, future product development, regulatory clearances and approvals, competitive position and expenditures. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and changes in circumstances. Actual future results and trends may differ materially from historical results or those reflected in any such forward-looking statements depending on a variety of factors. Solventum assumes no obligation to update or revise such statements, whether as a result of new information, future events or otherwise, except as required by applicable law. A further description of these factors is located under "Cautionary Note Regarding Forward-Looking Statements" and "Risk Factors" in Solventum's periodic reports on flle with the SEC. Solventum assumes no obligation to update any forward-looking statements discussed herein as a result of new information or future events or developments.
In addition to reporting flnancial results in accordance with U.S. GAAP, Solventum also provides non-GAAP measures that we use, and plan to continue using, when monitoring and evaluating operating performance and measuring cash available to invest in our business. The adjusted measures are not in accordance with, nor are they a substitute for GAAP measures. These non-GAAP flnancial measures are supplemental measures of our performance and our liquidity that we believe help investors understand our underlying business performance and Solventum uses these measures as an indication of the strength of Solventum and its ability to generate cash. Refer to the reconciliation schedules included in our earnings release dated May 5, 2026, which can be found on our investor relations website, for descriptions and reconciliations of flnancial measures. Solventum calculates forward-looking non-GAAP flnancial measures, including organic sales growth, adjusted gross margin, adjusted operating income, adjusted operating income margin, adjusted effective tax rate, adjusted earnings per share and free cash flow based on internal forecasts that omit certain amounts that would be included in GAAP flnancial measures. Solventum does not provide reconciliations of these forward-looking non-GAAP flnancial measures to the respective GAAP metrics as it is unable to predict with reasonable certainty and without unreasonable effort certain items such as the impact of changes in currency exchange rates, impacts associated with business acquisitions or divestitures and the timing and magnitude of restructuring activities, among other items. The timing and amounts of these items are uncertain and could have a material impact on Solventum's results in accordance with GAAP.
The Q1 2026 flnancial statements and flnancial information, including reconciliations of non-GAAP flnancial measures,
are available on Solventum's website: investors.solventum.com.
Q1 2026
Disclaimer
Solventum Corporation published this content on May 05, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 05, 2026 at 20:25 UTC.